Novel GAA gene mutation found in man with late-onset Pompe disease

Finding underscores the significance of reporting new variants

Written by Steve Bryson, PhD |

A magnifying glass hovers over a file contained in one of several folders.

A study details a previously unreported mutation, alongside a known mutation, in the GAA gene that caused LOPD in a 55-year-old man. (Photo from iStock)

Researchers reported a previously unreported mutation, alongside a known mutation, in the GAA gene that caused late-onset Pompe disease (LOPD) in a 55-year-old man.

“This finding underscores the significance of reporting new variants, especially in rare conditions such as Pompe disease, where each new contribution enhances diagnostic accuracy and can directly impact clinical management and genetic testing,” researchers wrote in the study, “A novel GAA variant reveals potential mechanisms of proteostasis disruption in late onset Pompe disease,” published in Scientific Reports.

Recommended Reading
A red teddy bear rests against the side of a sleeping baby.

Newborn screening finds more presumed LOPD cases than expected

Examining newly identified mutations is critical

Pompe is caused by GAA gene mutations that disrupt the activity of acid alpha-glucosidase, an enzyme that breaks down glycogen, a complex sugar molecule, inside cells. Without enough enzyme activity, glycogen builds up to toxic levels, interfering with organ and tissue function, particularly in the heart and other muscles.

While more than 900 GAA mutations have been reported so far, examining newly identified mutations remains essential. This is especially true for adult-onset disease, where symptoms can overlap with other neuromuscular disorders and may lead to misdiagnosis.

In this report, researchers in Italy described the case of a 55-year-old man with late-onset Pompe who harbored a novel GAA gene mutation.

He was of Peruvian origin and had lived in Italy for 10 years. Up to age 30, he was physically active, but at 40 he developed difficulty walking and climbing stairs, with increasingly frequent falls. At about 45 years, he had difficulty raising his arms, and since age 50, he has had shortness of breath when lying on his back and sleeps on his side as a result.

Earlier evaluations in Peru were inconclusive, and a diagnosis of muscular dystrophy had been proposed. His brother, age 57 and living in Lima, Peru, has difficulty walking, scapular winging (protruding shoulder blades), and shortness of breath with minimal exertion. The patient’s two daughters, ages 17 and 14, have normal motor development.

Recommended Reading
Two doctors react to information on a tablet.

Chronic pain affects more than 80% of late-onset Pompe disease patients

Blood tests detect bone loss, sign of muscle damage

Blood tests revealed elevated creatine kinase, a sign of muscle damage, and a bone assessment detected bone loss. He had a waddling gait, a positive Gowers’ maneuver (using his hands to push up his body when rising), and scapular winging on both sides.

Muscle strength tests found severe weakness in the hip muscles and hamstrings (back of thigh) and moderate weakness in the quadriceps (front of thigh). Muscle MRI showed marked fatty replacement, a sign of muscle breakdown, in the buttocks muscles and the back of the thigh.

Using electromyography, clinicians detected a chronic myopathic pattern, meaning the muscle fibers were affected rather than the nerves that control them. Echocardiography revealed mild thickening of the heart muscle. No abnormal beats were reported.

Lung function tests showed that his lungs were restricted from fully expanding, indicating respiratory muscle weakness when breathing in. He also had mild obstructive sleep apnea, meaning he stopped breathing while asleep. He began noninvasive ventilation, with “good compliance and clinical benefit.”

Lastly, a muscle biopsy of the outer thigh muscle found severe vacuolar myopathy, or abnormal fluid-filled spaces inside muscle fibers.

The results of this study expand the mutational landscape of the GAA gene and confirm the value of the integrated clinical-biochemical-genetic approach in the diagnosis of LOPD.

When the clinicians tested his acid alpha-glucosidase activity, it was significantly lower than the normal threshold. Subsequent genetic testing revealed two GAA mutations in compound heterozygosity, meaning a different mutation on each copy of the gene. One of these mutations was absent in Pompe databases. Both daughters had acid alpha-glucosidase activity within the normal reference range.

He began treatment every other week with the enzyme replacement therapy Nexviadyme (avalglucosidase alfa), which is sold as Nexviazyme in the U.S.

The researchers also used a software called STRING to explore proteins functionally associated with acid alpha-glucosidase. Among the strongest partners were enzymes involved in carbohydrate metabolism, including pancreatic amylase, which breaks down complex carbohydrates such as glycogen, and sucrase-isomaltase, which breaks down dietary carbohydrates.

The team noted that this does not necessarily imply a physical connection between the enzymes. They add that the predicted relationships “require further targeted experimental validation” before they can be considered causal mechanisms in Pompe disease.

“The results of this study expand the mutational landscape of the GAA gene and confirm the value of the integrated clinical-biochemical-genetic approach in the diagnosis of LOPD,” the researchers concluded.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.